BRAFV600E, KRASG12C mutation, ERBB2 (HER2) amplification, and various receptor tyrosine kinase (RTK) fusions are rare but potentially therapeutically relevant in colorectal cancer (CRC) (1, 2). Here, ERBB2 is linked to colorectal cancer.